FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| OMB APPROVAL | | | | | | | | | |
|--------------------------|-----------|--|--|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | | | |
| Estimated average burden | | | | | | | | | |
| hours por response: | 0.5 | | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person* Weiss Patrick | | | | | 2. Iss | 2. Issuer Name and Ticker or Trading Symbol Twist Bioscience Corp [TWST] | | | | | | | | | all appl | icable) | Person(s) to Is | | |
|--|---|--|---------|--|-------------------------------|---|--|---|------------------------------|--|---------------------------|--|-------------------------------|---|---|---|---|--|--|
| (Last) C/O TWIS | (Firs | t) (N ENCE CORPOR | Middle) |)N | | 3. Date of Earliest Transaction (Month/Day/Year) 01/21/2020 | | | | | | | | X | Director Officer (give title below) Chief Opera | | Other below | (specify | |
| 681 GATEWAY BLVD. | | | | | 4. If A | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | 6. Individual or Joint/Group Filing (Check Applicable Line) | | | | | |
| (Street) SOUTH SAN FRANCISCO CA 94080 | | | | | | | | | | | | | | | X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | |
| (City) | (Sta | te) (Z | Zip) | | | | | | | | | | | | | | | | |
| | | Table | e I - N | on-Deriv | ative | Secu | ıritie | es Ac | quired | , Dis | sposed of | f, or Be | nefici | ally (| Owne | d | | | |
| Date | | | Date | 2. Transaction Date (Month/Day/Year) | | | 2A. Deemed Execution Date, if any (Month/Day/Year) | | tion str. | 4. Securities Acquired (A) o Disposed Of (D) (Instr. 3, 4 | | | and 5) Secur Benef Owne | | cially I Following | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership | | |
| | | | | | | | | Code | v | Amount | (A) or (D) | Price | | | ted action(s) 3 and 4) | | (Instr. 4) | | |
| Common Stock | | | | 01/21/2 | 01/21/2020 | | | | S ⁽¹⁾ | | 598 | D | \$22.2 | .38 ⁽²⁾ | 9 | 5,628 | D | | |
| Common Stock 01/21 | | | | | 020 | | | | S ⁽¹⁾ | | 3,491 | D | \$22.2 | .298(3) | | 2,137 | D | | |
| Common Stock 01/22/20 | | | | |)20 | | | S ⁽¹⁾ | | 435 | D | \$22.2 | 27(4) | 9 | 1,702 | D | | | |
| Common Stock 01/22/2 | | | | |)20 | | | | S ⁽¹⁾ | | 163 | D | \$23. | \$23.06(5) | | 1,539 | D | | |
| Common Stock 01/22/20 | | | | |)20 | | | | S ⁽¹⁾ | | 2,468 | D | \$22.2 | 216(6) | 89,071 | | D | | |
| Common Stock 01/22/ | | | | | 020 | | | | S ⁽¹⁾ | | 1,023 | D | \$23.0 |)55 ⁽⁷⁾ | 88,048 | | D | | |
| | | Ta | ble II | | | | | | | | osed of, o convertible | | | | vned | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | if any | emed tion Date, n/Day/Year) | 4. Transa Code (I 8) | action of | | urities uired or oosed O) tr. 3, 4 | 6. Date Expirat (Month | tion D | | 7. Title a Amount Securitie Underlyi Derivativ Security and 4) | of es ing /e | of Dei Sed | f erivative ecurity nstr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4) | Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | |
| | | | | | Code | v | (A) (D) | | Date Exercisable | | Expiration Date | Amou or Numb of Title Share | | | | | | | |

Explanation of Responses:

- 1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
- 2. Represents the weighted average sales price per share. The shares sold at prices ranging from \$22.03 to \$22.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- 3. Represents the weighted average sales price per share. The shares sold at prices ranging from \$22.04 to \$22.97 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- 4. Represents the weighted average sales price per share. The shares sold at prices ranging from \$21.85 to \$22.81 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- 5. Represents the weighted average sales price per share. The shares sold at prices ranging from \$22.91 to \$23.25 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- 6. Represents the weighted average sales price per share. The shares sold at prices ranging from \$21.83 to \$22.74 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- 7. Represents the weighted average sales price per share. The shares sold at prices ranging from \$22.87 to \$23.36 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Remarks:

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.